Eesti - eesti - Ravimiamet

zentiva k.s. - fingolimood - kõvakapsel - 0,5mg 28tk; 0,5mg 30tk; 0,5mg 7tk; 0,5mg 56tk

Eesti - eesti - Ravimiamet

teva gmbh - fingolimood - kõvakapsel - 0,5mg 10tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 100tk; 0,5mg 30tk

Eesti - eesti - Ravimiamet

medochemie limited - fingolimood - kõvakapsel - 0,5mg 98tk; 0,5mg 28tk; 0,5mg 7tk; 0,5mg 10tk; 0,5mg 30tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - fingolimood - kõvakapsel - 0,5mg 60tk; 0,5mg 30tk; 0,5mg 98tk; 0,5mg 28tk; 0,5mg 14tk; 0,5mg 90tk; 0,5mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kiiresti arenev raske relapsing remitting sclerosis multiplex määratud 2 või enam puuet ägenemiste ühe aasta, ja on 1 või enam gadoliinium suurendada kahjustused aju mri või olulist kasvu, t2 kahjustus koormus võrreldes varasema hiljutise mrt.

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - fingolimood - kõvakapsel - 0,5mg 98tk; 0,5mg 28tk; 0,5mg 7tk

Eesti - eesti - Ravimiamet

gedeon richter plc. - fingolimood - kõvakapsel - 0,5mg 7tk; 0,5mg 98tk; 0,5mg 28tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Eesti - eesti - Ravimiamet

stada arzneimittel ag - fingolimood - kõvakapsel - 0,5mg 7tk; 0,5mg 28tk; 0,5mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.